| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Alpl |
| Uniprot No | P05186 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 29-138aa |
| 氨基酸序列 | WRDQAQETLKYALELQKLNTNVAKNVIMFLGDGMGVSTVTAARILKGQLH HNPGEETRLEMDKFPFVALSKTYNTNAQVPDSAGTATAYLCGVKANEGTV GVSAATERSR |
| 预测分子量 | 38 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于Alpl重组蛋白的参考文献摘要：
---
1. **文献名称**: *"Enzyme-replacement therapy in life-threatening hypophosphatasia"*
**作者**: Whyte MP, et al.
**摘要**: 该研究报道了使用重组组织非特异性碱性磷酸酶(TNSALP，即Alpl编码蛋白)治疗严重低磷酸酯酶症患儿。通过持续静脉注射重组酶，患儿骨骼矿化缺陷得到显著改善，并延长了生存期，证实了重组Alpl蛋白的临床潜力。
2. **文献名称**: *"Recombinant alkaline phosphatase for the treatment of chronic kidney disease"*
**作者**: Peters E, et al.
**摘要**: 探讨重组碱性磷酸酶(包括Alpl衍生蛋白)在慢性肾病模型中的抗炎和抗纤维化作用。实验显示其通过水解促炎因子ATP/ADP缓解肾脏损伤，为代谢性疾病治疗提供新策略。
3. **文献名称**: *"Production and characterization of recombinant human tissue-nonspecific alkaline phosphatase"*
**作者**: Sergienko E, et al.
**摘要**: 研究描述了通过哺乳动物细胞表达系统高效生产重组人TNSALP的方法，并验证其酶活性和稳定性。该蛋白可用于低磷酸酯酶症的机制研究及药物开发。
---
注：若需扩展文献范围，可进一步检索关键词如“recombinant ALPL bone regeneration”或“asfotase alfa clinical trial”获取更多研究。
**Background of ALPL Recombinant Protein**
Alkaline phosphatase, tissue-nonspecific isozyme (ALPL), also known as tissue-nonspecific alkaline phosphatase (TNSALP), is a key enzyme encoded by the *ALPL* gene in humans. It plays a critical role in regulating phosphate metabolism and mineralization processes, particularly in bone and teeth development. ALPL hydrolyzes phosphate esters to release inorganic phosphate, which is essential for skeletal mineralization. Mutations in the *ALPL* gene are linked to hypophosphatasia (HPP), a rare genetic disorder characterized by defective bone mineralization, dental abnormalities, and systemic complications ranging from mild to life-threatening severity.
Recombinant ALPL protein is produced using biotechnological methods, such as expression in mammalian cell lines (e.g., CHO or HEK293), to ensure proper post-translational modifications and functional activity. This engineered protein retains the enzymatic properties of native ALPL and is widely used in research to study HPP pathophysiology, bone biology, and potential therapeutic strategies. For instance, enzyme replacement therapy (ERT) using recombinant TNSALP (e.g., asfotase alfa) has become a breakthrough treatment for severe HPP, demonstrating improved survival and skeletal outcomes.
Beyond therapeutics, recombinant ALPL serves as a tool in biochemical assays, drug screening, and diagnostic development. Its applications extend to studying cellular signaling pathways, mineralization mechanisms, and interactions with substrates or inhibitors. Structural studies of recombinant ALPL also aid in understanding mutation-induced functional defects and designing targeted therapies. Overall, recombinant ALPL protein bridges translational research and clinical innovation, offering insights into both fundamental biology and therapeutic interventions for mineralization-related disorders.
×
